Departamento de Infectología, Clínica de Inmunoinfectología VIH, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Ciudad de México, México.
HIV Res Clin Pract. 2024 Dec;25(1):2411481. doi: 10.1080/25787489.2024.2411481. Epub 2024 Oct 8.
Diabetes affects 4.5% of people living with HIV in Mexico. This study aims to describe the diabetes cascade of care (DMC) in people with HIV in a tertiary center in Mexico City.
We conducted a single-center review of people with HIV aged over 18, using medical records of active people enrolled at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) HIV Clinic (HIVC). Our analysis focused on their last visit to describe the DMC, aiming to identify gaps in control goals. We included people who had a consultation within the 12 months preceding May 2020.
Out of the 2072 active people, medical records were available for 2050 (98.9%). Among these, 326 people (15.9%) had fasting glucose (FG) abnormalities, of which 133 (40.7%) had diabetes. The prevalence of diabetes among people with HIV was of 6.4% (133/2050). Regarding the DMC, the following proportions of people achieved control goals: 133/133 (100%) received medical care in the last 12 months, 123/123 (100%) had blood pressure (BP) <140/90 mmHg, 73/132 (55.3%) had LDL cholesterol (c-LDL) <100 mg/dl, 63/132 (47.7%) had FG <130 mg/dl, 50/116 (43.1%) had glycosylated hemoglobin (HbA1c) <7%. ABC goals (HbA1c <7%, c-LDL <100 mg/dl, BP <140/90 mmHg) were met in 28/109 (25.6%) people. 126/133 (94%) people with HIV achieved HIV-viral load <50 copies/mL.
Despite the high rate of viral suppression among people with HIV and diabetes, significant challenges remain in achieving comprehensive diabetes control. These findings highlight the need for targeted interventions to improve metabolic outcomes and the overall management of diabetes in people with HIV.
在墨西哥，4.5%的艾滋病毒感染者患有糖尿病。本研究旨在描述墨西哥城一家三级中心的艾滋病毒感染者的糖尿病管理流程。
我们对年龄在 18 岁以上的艾滋病毒感染者进行了单中心回顾性研究，使用了在墨西哥国立医学与营养研究所萨尔瓦多·祖比兰艾滋病毒诊所（HIVC）登记的活跃感染者的病历。我们的分析重点是他们最近一次就诊，以描述糖尿病管理流程，旨在发现控制目标方面的差距。我们纳入了在 2020 年 5 月前的 12 个月内有就诊记录的感染者。
在 2072 名活跃感染者中，有 2050 名（98.9%）的病历可用。其中，326 名（15.9%）空腹血糖（FG）异常，其中 133 名（40.7%）患有糖尿病。艾滋病毒感染者中糖尿病的患病率为 6.4%（133/2050）。关于糖尿病管理流程，达到控制目标的患者比例如下：133/133（100%）在过去 12 个月内接受了医疗护理，123/123（100%）血压（BP）<140/90mmHg，73/132（55.3%）低密度脂蛋白胆固醇（c-LDL）<100mg/dl，63/132（47.7%）空腹血糖（FG）<130mg/dl，50/116（43.1%）糖化血红蛋白（HbA1c）<7%。28/109（25.6%）人达到了 ABC 目标（HbA1c<7%，c-LDL<100mg/dl，BP<140/90mmHg）。133/133（94%）艾滋病毒感染者的病毒载量<50 拷贝/ml。
尽管艾滋病毒感染者的病毒抑制率很高，但在实现全面糖尿病控制方面仍存在重大挑战。这些发现强调了需要采取有针对性的干预措施，以改善代谢结果和艾滋病毒感染者的整体糖尿病管理。
